<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">

  <title>NICE Formulary - NALOXONE HYDROCHLORIDE</title>

  <meta name="X-UA-Compatible" content="IE=edge,chrome=1">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0">
  <meta name="description" content="">
  <meta name="author" content="NICE - The National Institute of Health and Care Excellence">

  <!--[if lt IE 9]>
  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/html5shiv.js"></script>
  <![endif]-->

  <!-- Le styles -->
  <link rel="stylesheet" href="http://mattonfoot.github.io/NICE.UI/styles/ui.css">

  <!-- Fav and touch icons -->
  <link rel="shortcut icon" href="http://cdn.nice.org.uk/V3/Content/nice/favicon.ico">
  <link rel="apple-touch-icon-precomposed" href="http://cdn.nice.org.uk/V3/Content/nice/favicon-152.png">
  <meta name="msapplication-TileColor" content="#fafafb">
  <meta name="msapplication-TileImage" content="http://cdn.nice.org.uk/V3/Content/nice/favicon-144.png">

  <style>
  .tab-content {
    overflow: auto;
  }
  .tab-content > .tab-pane {
    display: none;
  }
  .tab-content > .active {
    display: block;
  }

  header .nav {
    list-style: decimal inside none;
  }
  header .nav > li {
    display: list-item;
  }
  header .nav > li > a {
    display: block;
    margin: 0;
    padding: 0;
    text-decoration: none;
    color: #01769d;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus,
  header .nav > li.active > a,
  header .nav > li.active > a:hover,
  header .nav > li.active > a:focus {
    outline: 0;
    color: #08455b;
    background: transparent;
    text-decoration: none;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus {
    text-decoration: underline;
  }

  [outputclass="title"],
  .title {
    font-size: 19px;
    font-size: 1.9rem;
    line-height: 24px;
    line-height: 2.4rem;
  }

  h3, h4, h5, h6, .title, [outputclass="title"] {
    margin-bottom: 0;
  }

  h1+p, h2+p, h3+p, h4+p, h5+p, h6+p, .title+p, [outputclass="title"]+p {
    margin-top: 0;
  }

  .doses {
    padding-left: 0;
    list-style: none;
  }
  .doses .dose {
    padding-left: 24px;
    padding-left: 2.4rem;
    margin-bottom: 6px;
    margin-bottom: .6rem;
  }
  .doses .adult {
    border-left: 7px solid #346e7f;
  }
  .doses .child {
    border-left: 7px solid #82176F;
  }

  /* DITA symbols */

  ph {
    color: #006;
  }

  tm::before {
    font-size: .8em;
    margin-left: -.2em;
    vertical-align: top;
  }
  tm[tmtype="reg"]::before {
    content: "\00ae";
  }
  tm[tmtype="copy"]::before {
    content: "\00a9";
  }
  tm[tmtype="trade"]::before {
    content: "\2122";
  }

  </style>
</head>

<body id="" class="">
  <header>
    <div class="container">
      <ul class="breadcrumb">
        <li><a href="../">Home</a> <span class="divider glyph-chevron-right"></span></li>
        <li class="active"><a href="../drug/">Drugs</a></li>
      </ul>

      <h1>NALOXONE HYDROCHLORIDE</h1>


      <nav>
        <ul class="nav nav-list">

          <li class="active"><a href="#indicationsAndDoses" data-toggle="tab">Indications and doses</a></li>
          <li><a href="#pregnancy" data-toggle="tab">Pregnancy</a></li>
          <li><a href="#sideEffects" data-toggle="tab">Side effects</a></li>
          <li><a href="#directionsForAdministration" data-toggle="tab">Administration</a></li>
          <li><a href="#importantSafetyInformation" data-toggle="tab">Important safety information</a></li>
          <li><a href="#cautions" data-toggle="tab">Cautions</a></li>
          <li><a href="#unlicensedUse" data-toggle="tab">Unlicensed use</a></li>
          <li><a href="#medicinalForms" data-toggle="tab">Medicinal forms</a></li>
        </ul>
      </nav>

      <br/>
    </div>
  </header>

  <div class="container">
    <div class="tab-content">

      <section class="tab-pane active" id="indicationsAndDoses">
        <h2>Indications and doses</h2>

        <section class="indicationAndDoseGroups">
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Overdosage with opioids</span>,
            </h4>
            <p class="specificity"><span class="route">By continuous intravenous infusion</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Initially 400 micrograms, then 800 micrograms for up to 2 doses at 1 minute intervals if no response to preceding dose, then increased to 2 mg for 1 dose if still no response, then review diagnosis; further doses may be required if respiratory function deteriorates, 4 mg dose may be required in seriously poisoned patients.</li>
              <li class="dose adult"><strong>For adults </strong><br/>
                Using an infusion pump, adjust rate according to response (initially, rate may be set at 60% of the initial resuscitative intravenous injection dose per hour). The initial resuscitative intravenous injection dose is that which maintained satisfactory ventilation for at least 15 minutes.</li>
              <li class="dose child"><strong>For children 1 month&#8211;11 years</strong><br/>
                Initially 100 micrograms/kg, if no response, repeat at intervals of 1 minute to a total max. 2 mg, then review diagnosis; further doses may be required if respiratory function deteriorates.</li>
              <li class="dose child"><strong>For children 12&#8211;17 years</strong><br/>
                Initially 400 micrograms, then 800 micrograms for up to 2 doses at 1 minute intervals if no response to preceding dose, then increased to 2 mg for 1 dose if still no response, then review diagnosis; further doses may be required if respiratory function deteriorates, 4 mg dose may be required in seriously poisoned patients.</li>
              <li class="dose child"><strong>For children </strong><br/>
                Using an infusion pump, adjust rate according to response (initially, rate may be set at 60% of the initial resuscitative intravenous injection dose per hour). The initial resuscitative intravenous injection dose is that which maintained satisfactory ventilation for at least 15 minutes.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Overdosage with opioids in a non-medical setting</span>,
            </h4>
            <p class="specificity"><span class="route">By intramuscular injection</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                400 micrograms every 2&#8211;3 minutes, to be injected into deltoid region or anterolateral thigh. Each dose given in subsequent resuscitation cycles if patient not breathing normally, continue until consciousness regained, breathing normally, medical assistance available, or contents of syringe used up.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Reversal of postoperative respiratory depression</span>,
            </h4>
            <p class="specificity"><span class="route">Initially by intravenous injection</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Initially 100&#8211;200 micrograms, alternatively (by intravenous injection) initially 1.5&#8211;3 micrograms/kg, then (by intravenous injection) 100 micrograms every 2 minutes, alternatively (by intramuscular injection) 100 micrograms every 1&#8211;2 hours if response inadequate.</li>
              <li class="dose child"><strong>For children 1 month&#8211;11 years</strong><br/>
                1 microgram/kg, repeated every 2&#8211;3 minutes if required.</li>
              <li class="dose child"><strong>For children 12&#8211;17 years</strong><br/>
                Initially 100&#8211;200 micrograms, alternatively (by intravenous injection) initially 1.5&#8211;3 micrograms/kg, then (by intravenous injection) 100 micrograms every 2 minutes, alternatively (by intramuscular injection) 100 micrograms every 1&#8211;2 hours if response inadequate.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Reversal of respiratory and CNS depression resulting from opioid administration to mother during labour</span>,
            </h4>
            <p class="specificity"><span class="route">By intravenous injection or by subcutaneous injection</span></p>
            <ul class="doses">
            </ul>
          </section>
        </section>
        
        
        
        
            <section class="pharmacokinetics">
              <h3>Pharmacokinetics</h3>
              <p>Naloxone has a short duration of action; repeated doses or infusion may be necessary to reverse effects of opioids with longer duration of action.</p><p>
        <b>Important:</b> Only give by subcutaneous or intramuscular routes if intravenous route is not feasible; intravenous administration has more rapid onset of action.</p>
            </section>
        
      </section>



      <section class="tab-pane" id="pregnancy">
        <h2>Advice when patient is pregnant</h2>

            <section class="generalInformation">
              <p>Use only if potential benefit outweighs risk.</p>
            </section>
      </section>




      <section class="tab-pane" id="sideEffects">
        <h2>Known side effects</h2>

          <h3>General side effects</h3>
              <p>
                <strong>commonOrVeryCommon:</strong> Cardiac arrest in children, dizziness, dyspnoea in children, headache, hypertension, hyperventilation in children, hypotension, nausea, pulmonary oedema in children, tachycardia, ventricular fibrilation in children, vomiting,
              </p>
              <p>
                <strong>uncommon:</strong> Agitation in children, arrhythmia in adults, bradycardia in adults, diarrhoea, dry mouth, excitement in children, hyperventilation in adults, paraesthesia in children, sweating, tremor,
              </p>
              <p>
                <strong>rare:</strong> Seizures in adults,
              </p>
              <p>
                <strong>veryRare:</strong> Anaphylaxis in adults, cardiac arrest in adults, erythema multiforme, hypersensitivity reactions in adults, pulmonary oedema in adults, seizures in children, ventricular fibrillation in adults,
              </p>
              <p>
                <strong>notKnown:</strong> Agitation in adults,
              </p>
        
        
        
      </section>

      <section class="tab-pane" id="directionsForAdministration">
        <h2>Directions for administration</h2>

            <section class="directionsForAdministration">
              <h3 class="specificity">With <ph outputclass="route">intravenous</ph> use in children</h3>
              <p>For <i>continuous intravenous infusion</i>, dilute to a concentration of up to 200&#8239;micrograms/mL with Glucose 5% or Sodium Chloride 0.9%.</p>
            </section>
            <section class="directionsForAdministration">
              <h3 class="specificity">With <ph outputclass="route">intravenous</ph> use in adults</h3>
              <p>For <i>intravenous infusion</i> (<i>Minijet</i>
            <tm tmtype="reg"/> Naloxone Hydrochloride), give continuously in Glucose 5% or Sodium Chloide 0.9%. Dilute to a concentration of up to 200&#8239;micrograms/mL and administer via an infusion pump.</p>
            </section>
      </section>



      <section class="tab-pane" id="importantSafetyInformation">
        <h2>Important safety information</h2>

            <section class="importantSafetyInformation">
                <h3>Safe practice</h3>
              <p>Doses used in acute opioid overdosage may not be appropriate for the management of opioid-induced respiratory depression and sedation in those receiving palliative care and in chronic opioid use.</p>
            </section>
      </section>

      <section class="tab-pane" id="cautions">
        <h2>Cautions regarding administration</h2>

        <ul>
          <li>
            Cardiovascular disease or those receiving cardiotoxic drugs (serious adverse cardiovascular effects reported)
          </li>
          <li>
            maternal physical dependence on opioids (may precipitate withdrawal in newborn)
          </li>
          <li>
            pain
          </li>
          <li>
            physical dependence on opioids (precipitates withdrawal)
          </li>
        </ul>
        <ul>
          <li>
            <p>In postoperative use, the dose should be titrated for each patient in order to obtain sufficient respiratory response; however, naloxone antagonises analgesia.</p>
          </li>
        </ul>
      </section>



      <section class="tab-pane" id="unlicensedUse">
        <h2>Unlicensed use</h2>

            <section class="unlicensedUse">
              <p>Naloxone doses in BNF may differ from those in product literature.</p>
            </section>
      </section>










      <section class="tab-pane" id="medicinalForms">
        <h2>Prepared medicinal forms of NALOXONE HYDROCHLORIDE</h2>


            <section class="licensingVariationStatement">
              <p>There can be variation in the licensing of different medicines containing the same drug.</p>
            </section>
        

            <div id="PHP75571"><a href="../medicinalForm/PHP75571.html" data-target="#PHP75571" data-action="load">Solution for injection</a></div>
      </section>
    </div>
  </div>

  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/jquery.js"></script>
  <script src="http://cdn.nice.org.uk/V3/Scripts/twitter.bootstrap.js"></script>
  <script src="/content/scripts/NICE.RemoteLoad.js"></script>
</html>
